Weight gain and metabolic syndrome among young patients on antipsychotic medication: What do we know and where do we go?

Australasian Psychiatry

Volumn 19, Issue 3, 2011, Pages 232-235

  Eapen, Valsamma ^a,c   John, George ^b  

^a Sydney South West Area Health Service ^*  (Australia)

^b Cygnet Hospital Godden Green   (United Kingdom)

^c LIVERPOOL HOSPITAL   (Australia)

Author keywords

metabolic syndrome; psychosis; second generation antipsychotics; weight gain; young people

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; BODY IMAGE; BODY MASS; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; METABOLIC SYNDROME X; OBESITY; PATHOGENESIS; PATIENT COMPLIANCE; PSYCHOPHARMACOTHERAPY; SELF ESTEEM; SIDE EFFECT; SOCIAL DISCRIMINATION; STIGMA; WEIGHT GAIN;

ADOLESCENT; ADOLESCENT BEHAVIOR; ANTIPSYCHOTIC AGENTS; FORECASTING; HUMANS; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; WEIGHT GAIN;

EID: 79959460019     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.3109/10398562.2010.539609     Document Type: Article

References (30)

1. Armenteros JL, Davies M. Antipsychotics in early onset schizophrenia: systematic review and meta-analysis. European Child and Adolescent Psychiatry 2006; 15: 141-148.
2. Olfson M, Blanco C, Liu L et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 2006; 63: 679-685. (Pubitemid 43848299)
3. Patel NC, Crismon ML, Hoagwood K et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. Journal of American Academy of Child and Adolescent Psychiatry 2005; 44: 548-556. (Pubitemid 40720954)
4. Ratzoni G, Gothelf D, Brand-Gothelf A et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. Journal of American Academy of Child and Adolescent Psychiatry 2002; 41: 337-343. (Pubitemid 38338156)
5. Sikich L, Hamer RM, Bashford RA et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind randomized, 8-week trial. Neuropsychopharmacology 2004; 29: 133-145. (Pubitemid 38068023)
6. Tailor AM, Peeters PH, Norat T, Vineis P, Romaguera D. An update on the prevalence of the metabolic syndrome in children and adolescents. International Journal of Pediatric Obesity. 2010; 5: 202-213.
7. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of American Academy of Child and Adolescent Psychiatry 2006; 45: 771-791. (Pubitemid 43932904)
8. World Health Organization. Controlling the global obesity epidemic. Available fromURL: http://www.who.int/nut/obs.html 2002.
9. Janssen I, Katzmarzyk PT, Srinivasa SR et al. Utility of childhood BMI in the prediction of adulthood disease: comparison of national and international references. Obesity Research 2005; 13: 1106-1115.
10. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Canadian Journal of Psychiatry 2006; 51: 492-501. (Pubitemid 44166337)
11. Magarey AM, Daniels LA, Boulton TJ et al. Predicting obesity in early adulthood from childhood and parental obesity. International Journal of Obesity and Related Metabolic Disorders 2003; 27: 505-513. (Pubitemid 36520851)
12. Burke V. Obesity in childhood and cardiovascular risk. Clincal and Experimental Pharmacology and Physiology 2006; 33: 831-837. (Pubitemid 44215139)
13. Alvarez-Jimenez M, González-Blanch C, Crespo-Facorro B et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008; 22: 547-562. (Pubitemid 351822117)
14. Fleischhaker C, Heiser P, Hennighausen K et al. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. Journal of Neural Transmission 2007; 114: 273-280. (Pubitemid 46147166)
15. Fleischhaker C, Heiser P, Hennighausen K et al. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. Journal of Child and Adolescent Psychopharmacology 2006; 16: 308-316. (Pubitemid 43902427)
16. Shaw P, Sporn A, Gogtay N et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Archives of General Psychiatry 2006; 63 721-730.
17. Fraguas D, Merchán-Naranjo J, Laita P et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. Journal of Clinical Psychiatry. 2008; 69: 1166-1175. (Pubitemid 352031601)
18. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents. Findings from the Third National Health and Nutrition Examination Survey, 1988-1994. Archives of Pediatric Adolescent Medicine 2003: 157: 821-827. (Pubitemid 36988016)
19. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. Journal of Clinical Psychiatry 2007; 68: 8-13. (Pubitemid 46762118)
20. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioural therapy on weight loss in overweight and obese patients with schizophrenia or schizoaf-fective disorder. Journal of Clinical Psychiatry 2005; 66: 205-212. (Pubitemid 40314327)
21. Kwon JS, Choi JS, Bahk WM et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder. A 12-week randomized controlled clinical trial. Journal of Clinical Psychiatry 2006; 67: 547-553. (Pubitemid 43764231)
22. Biddle SJH, Mutrie N. Psychology of Physical Activity: Determinants, Well-being, and Interventions. London: Routledge, 2001.
23. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Services 2003; 54: 565-567. (Pubitemid 36752990)
24. Aronne LJ. Epidemiology, morbidity, and treatment of overweight and obesity. Journal of Clinical Psychiatry 2001; 62: S13-S22.
25. Fraguas D, Kirchoff D. Pharmacogenetics of antipsychotic-induced weight gain. Medical Science Monitor 2006; 12: LE6-LE7.
26. Correll CU, Manu P, Olshanskiy V et al. Cardiometabolic risk of second generation antipsychotic medications during first-time use in children and adolescents. Journal of American Medical Association 2009; 302: 1765-1773.
27. Walter G, DeLaroche A, Soh N et al. Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry 2008; 16: 253-262.
28. Ellis D, Shirzadi K, Grzeskowiak L, Angley M. Development of a novel program to facilitate monitoring physical health and adverse effects in children and adolescents prescribed antipsychotic medication. Australasian Psychiatry 2008; 16: 368-369.
29. Nguyen D, Brakoulias V, Boyce P. An evaluation of monitoring practices in patients on second generation antipsychotics. Australasian Psychiatry 2009; 17: 295-299.
30. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic non-compliance. Schizophrenia Research 2004; 66: 51-57. (Pubitemid 38030344)